Table 3. The number of events and crude event rates per 100 person-years of outcomes in anticoagulated patients with AF.
| Outcome | No polypharmacy (<5 drugs) | Polypharmacy (≥5 drugs) | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall polypharmacy | VKA | NOAC | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | ||
| Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | |
| Effectiveness | ||||||||
| Stroke/SE | 1,953 (1.78) | 5,427 (2.55) | 1,276 (3.71) | 4,151 (2.33) | 658 (2.34) | 1,770 (2.25) | 1,447 (2.38) | 276 (2.61) |
| Ischemic stroke | 1,008 (0.91) | 2,887 (1.34) | 643 (1.84) | 2,244 (1.25) | 403 (1.42) | 963 (1.21) | 748 (1.22) | 130 (1.22) |
| All-cause mortality | 4,555 (4.09) | 20,298 (9.34) | 3,584 (10.11) | 16,714 (9.19) | 2,098 (7.28) | 6,995 (8.71) | 6,474 (10.42) | 1,147 (10.74) |
| Safety | ||||||||
| Major bleeding | 3,306 (3.05) | 11,410 (5.48) | 2,119 (6.27) | 9,291 (5.32) | 1,352 (4.89) | 4,318 (5.65) | 2,819 (4.69) | 802 (7.74) |
| Intracranial bleeding | 945 (0.86) | 2,857 (1.33) | 593 (1.70) | 2,264 (1.26) | 366 (1.29) | 1,057 (1.34) | 694 (1.13) | 147 (1.38) |
| Gastrointestinal bleeding | 1,684 (1.53) | 5,969 (2.80) | 936 (2.69) | 5,033 (2.82) | 750 (2.65) | 2,424 (3.09) | 1,403 (2.30) | 456 (4.34) |
Abbreviations: NOAC, non-vitamin K antagonist oral anticoagulant; PY, person-year; SE, systemic embolism; VKA, vitamin K antagonist.